Elevance Health, Inc. (ELV) · Oct 21, 2026 · Earnings
Beat — Adjusted EPS $6.99 vs ~$4.66 consensus
Elevance Health’s third-quarter earnings beat consensus and lifted full-year guidance, but core Health Benefits profits and membership continued to shrink.
Elevance is trying to rebalance its insurance-heavy model: Medicare Advantage, Medicaid, and employer risk membership are shrinking, while premium increases, Carelon pharmacy/services, and targeted technology and operating investments are expected to support the next earnings phase. That backdrop was already visible after the second-quarter report, which flagged the same membership pressure and raised 2026 guidance.
| Metric | Q3 2026 | Q3 2025 / expectation | Read |
|---|---|---|---|
| Adjusted diluted EPS | $6.99 | ~$4.66 consensus | Large beat |
| Diluted EPS | $6.27 | $5.32 | Up 17.9% |
| Operating revenue | $50.4B | $50.1B | Up 0.7% |
| Adjusted operating gain | $1.3B | $1.3B | Essentially flat |
| Adjusted operating margin | 2.7% | 2.7% | In line |
| FY 2026 adjusted EPS guide | At least $29.00 | Previously at least $27.00 | Raised |
The headline is a clear earnings beat and another guidance increase. Adjusted diluted EPS of $6.99 was far above the published consensus near $4.66, while management raised its full-year adjusted EPS target to at least $29 from the prior $27 floor. The quarter also benefited from lower amortization and other below-operating-line items, so the GAAP-to-adjusted gap matters; nevertheless, the operating result was not a miss. 〔0〕
Carelon is doing the strategic heavy lifting. Carelon revenue rose 5% to $19.3 billion, and operating gain increased 17% to $0.9 billion, led by Carelon Services risk-based solutions and better specialty-pharmacy profitability. This is the part of the portfolio currently expanding margins and helping offset weakness in the legacy insurance segment.
The core Health Benefits business remains the unresolved issue. Revenue grew 3% to $43.4 billion, but operating gain fell 28% to $0.4 billion and margin compressed to 1.0% from 1.4%. Membership declined 1.1% year over year to 44.9 million, including a 15.5% drop in Medicare Advantage and a 4.9% decline in Medicaid. 〔1〕 Management attributes the profit pressure partly to targeted investments, but the mix shift toward smaller government and risk-based enrollment still leaves the insurance engine less profitable.
Underlying operating momentum was steady rather than accelerating. Total adjusted operating gain fell slightly year over year and adjusted operating margin was unchanged at 2.7%; the large EPS increase therefore reflects more than broad-based operating expansion, including a lower share count and stronger investment income. Operating expense rose 9.1%, with the adjusted expense ratio up 90 basis points, confirming that the company is spending ahead of the promised 2027 growth recovery.
Bottom line: This materially improves the near-term earnings story: Elevance beat a low bar and raised guidance again, with Carelon providing the growth engine. But the filing does not show a clean recovery in core Health Benefits profitability; it shows a successful offset, not a full repair, of that pressure.
Q4 results, expected late January 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!